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ABSTRACT: Pushkaramooladi choorna was tried clinically in Tamaka shvasa (Bronchial 
asthma) for a period of 45 days in concecutive 3 followups.  The clinical, labortary and 
pulmonary function tests carried out show significant antiasthmatic effect. 
 
INTRODUCTION 
 
Tamaka shvasa which has been mentioned 
in Ayurvedic classics similarises with the 
Bronchial asthma. Bronchial asthma, one of 
the most important ailments pertaining to the 
respiratory disorders.  Since the last two 
decades the prevalence rate increased to 
50% due to the pollutant allergants and 
changing environmental conditions.  Charka 
has given a three drug sati, pushkara, 
Amalaki combination in Shvasa chikitsa 
(Cha. Chi 17/129). These three drugs can act 
at three levels of pathogenesis, sati acts as 
an antiinflam-matory, pushkara as a 
bronchodilator and amalaki as an 
immunomodulator as well as antiviral.  This 
combination had been chosen for trial. 
 
MATERIALS AND METHODS  
 
Twenty five patients having bronchial 
asthma were randomly selected from the 
O.P.D. and I.P.D. of S.S. Hospital, Banaras 
Hindu University. The patients were 
diagnosed on the basis of detailed 
questionnaire along the symptoms given 
below, taken as subjective:  
 
-  Symptoms of breathlessness, 
duration with exertion or at least 
nocturnal or early morning, 
frequency, seasonal variation. 
-  Wheezing or whistling of chest any 
time. 
-  Paroxysmal cough or nocturnal 
paroxysmal cough with or without 
expectoration, colour, consistency.  
-  Tightness, heaviness or pain in the 
chest. 
-  Whether aggregation relation to 
exposure of dust, smoke, fumes and 
allergens. 
-  Any associated symptos of sinusitis, 
rhinitis. 
-  Family history of atopy/ allergic 
tendency. 
 
Objective Criteria for Diagnosis  
 
Pulmonary function test: Spirometric test 
had been done with the Electronic 
microplous spirometer of micromedical 
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Ltd.., Rochester, Kent, England, FEV1, 
FVC, FVR and PEFR were recorded. 
Average of three readings had been taken. 
FEV1 in percentage was calculated form 
predicted values mentioned in spirometric 
calculator based on patients sex, age, height 
and weight. FVC and PEFR were also 
calculated.  The pulmonary impairment was 
assessed by criteria based on the 
recommendation of the American thoracic 
society. 
 
Table -1 
Spirometric criteria for assigning pulmonary impairment 
 
Test Normal  Mild  Moderate  Severe 
FEV1 >80%  61-80  50-60  <  50% 
FVC >80%  61-80  50-60 <  50% 
PERF >80%  61-80 50-60  <  50% 
   
Laboratory investigations: 
 
Blood examination: TLC, DLC, AEC (Absolute Eosinophil Count). 
 
Sputum: for AFB and culture. 
 
ECG: to exclude cardiac disease. 
 
Preparation of drug and mode of 
administration 
 
The equal part of rhizomes of Sati 
(H.spicatum, Rose.), the roots of Pushkara 
(Innula racemosa, Linn) and fruits of 
Amalaki (Emblica officinalis, Linn). After 
removing the seeds were fine powdered. 
Nine grams of the power has been given in 3 
divided doses with honey.  The effect of the 
drug was assessed fortnightly for a period of 
6 weeks. In acute exacerbation the patient 
was advised to take the medication to relieve 
the asthmatic attack and asked them to note 
the kind of medicine used, the quantity and 
number of times. 
 
Parameters for assessment of the 
response of the trial/ drug  
 
A) Subjective parameters 
 
i) Dyspnoea: Dyspnoea has been classified 
in following grades according to NYMA 
criteria. 
 
Grade 1: Dyspnoea on more than 
accustomed work. 
 
Grade 2: Dyspnoea on accustomed work. 
 
Grade 3: Dyspnoea while doing less than 
accustomed work. 
 
Grade 4: Dysponea on rest  
 
ii) Cough: 
 
Grade 0: No cough 
 
Grade 1: Frequency two times in 24 hrs 
without exhaustion. 
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Grade 2: Frequency 3-6 times in 24 hrs with 
or without exhaustion. 
 
Grade 3 : Frequency more than 6 times in 24 
hrs with exhaustion. 
 
iii) Wheezing: 
 
Grade 0: No wheezing 
Grade 1: One or two times in a day 
Grade 2: During night time  
Grade 3: Throughout the day 
 
iv) Days of asthma per week (DA), 
frequency of asthmatic attach per week 
(FA), Severity of asthmatic attack (SA) were 
also assessed. 
 
B) Objective parameters 
 
i) Forced expiratory volume in one second 
(FEV1) 
 
ii) Forced vital capacity (FVC) 
 
iii) Peak expiratory flow rate (PEFR) 
 
iv) Respiratory rate (RR) 
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RESULT  
 
Table -2 
Response of pushkaramooladi choorna in clinical and objective parameters. 
 
Clinical 
objective 
criteria 
B.T. 
M.G.S.± S.D 
AT1 
M.G.S.± S.D(t) 
AT2 
M.G.S.± S.D(t) 
AT3 
M.G.S.± S.D(t) 
Dyspnoea  2.72 ±0.73  2.48±0.82(<0.05)  2.32 ±0.852(<0.001)  2.00 ± 0.91(<0.001) 
Cough  2.4 ±0.70  2.12 ± 0.72(<0.05)  2.04 ±0.8(<0.01)  1.92 ± 0.90(<0.01) 
Wheezing  2.44 ±0.88  2.12 ± 0.88 (<0.01)  2.00 ±0.91(<0.001)  1.64 ± 1.25(<0.001) 
D.A  4.56 ±1.93  4.24 ± 1.96(<0.05)  4.20 ±1.75(<0.02)  4.16 ± 1.92(<0.01) 
F.A  2.96± 0.98  2.68 ± 1.44(<0.05)  2.64 ±1.07(<0.01)  2.2 ±1.32(<0.01) 
S.A  3.52 ±1.22  3.8 ± 1.47 (<0.02)  3.92 ±1.49(<0.001)  3.36 ± 1.56(<0.001) 
R.R  34.28±8.0  32.84 ± 8.64(<0.02)  32.26 ±8.43(<0.001)  31.44 ± 8.25(<0.001) 
FEV  62.6± 15.06  62.81 ± 15.3(<0.05)  63.06±15.78 (<0.05)  63.45 ± 15.9(<0.01) 
FVC  2.03 ±0.53  2.16 ± 0.37(<0.05)  2.28 ±0.42 (<0.02)  2.81 ± 0.33(<0.01) 
FEFR  189.04 ±44.05 199.16 ± 42.25 (<0.02)  196.48±43.08 
(<0.001) 
199.6 ± 41.58(<0.001) 
BT: Before Treatment AT: After Treatment
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DISCUSSION 
 
The results of the clinical study confirm the 
anti-asthmatic activity of the compound 
drug pushkara, Sati and amalaki.  There was 
significant decrease in the mean grade score 
of dyspnoea after 2 wks, 4wks and 6 wks of 
treatment.  Cough, wheezing, days of asthka 
per week, frequency of attacks per week, 
severity of attack and respiratory rate shows 
significant effect after 2 wks of treatment, 
FEV1 and FVC results not showing 
significant after two weeks of treatment but 
it was significant after 4 and 6 wks of 
treatment. 
 
Now bronchial asthma is recognized as 
primarily an inflammatory disorder leading 
to bronchospasm and microvascular leakage.  
There is a great role of immuno system in 
the pathogenesis of asthma.  The three drug 
combination can act at three levels of 
pathogenesis, ie. Anti-inflamatory, 
bronchodilator and immunomodulatory.   
Sati acts as an anti-inflammatory, pushkara 
acts as a bronchodilator and Amalaki as an 
immunomodulator. 
 
Since it was a random study, it needs a 
specific sampling study of every type of 
asthma, i.e., episodic, chronic intermittent 
and chronic persistant asthma.  However, it 
needs biochemical, immunological and 
experimental study to establish the mode of 
action of this compound preparation 
“Pushkaramooladi choorna”. 
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